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Background/Aims: To investigate serological patterns of 
hepatitis B based on electrochemiluminescent immunoas-
says and the distribution characteristics of these patterns 
in hospitalized children and adolescents in Zhejiang, China 
between 2006 and 2010. Methods: Five serological mark-
ers, including hepatitis B surface antigen (HBsAg), hepatitis 
B e antigen (HBeAg), antibody to hepatitis B surface antigen 
(anti-HBs), antibody to hepatitis B e antigen (anti-HBe), and 
antibody to hepatitis B c antigen (anti-HBc), were chosen as 
a routine panel to monitor hepatitis B virus (HBV) infection 
and vaccination efﬁ  cacy. A total of 33,187 children (21,187 
boys and 12,000 girls) were selected using the following 
exclusion criteria: a previous diagnosis of hepatitis, age >16 
years or an address outside of Zhejiang. Results:  The aver-
age HBV vaccination coverage rates among 20,766 boys 
and 11,782 girls were 98.62% and 98.68%, respectively. 
Seventeen serological patterns of hepatitis B were found, 
and the dominant pattern was ‘anti-HBs (+) alone’ (62.03%) 
followed by ‘negative pattern’ (23.46%). The rates of the 
other 15 patterns ranged from 8.14% to 0.003%. Of 236 
HBsAg-positive patients, the overall rate of seropositivity was 
0.71%. The anti-HBs levels were grouped into 3 ranges (10-
100 mIU/mL, 100-1,000 mIU/mL, and >1,000 mIU/mL) for 
all anti-HBs-positive children (36.08%, 43.43%, and 20.49%, 
respectively). Conclusions: A low HBsAg carrier rate and a 
relatively high anti-HBs positive rate are present in hospital-
ized children and adolescents in Zhejiang. The distribution 
of serological patterns is associated with age but is mostly 
independent of gender. (Gut Liver 2011;5:210-216)
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INTRODUCTION
Hepatitis B virus (HBV) infection is a public health problem 
and classification of an HBV infection requires the identification 
of several serologic markers.
1 There are five serological markers 
including hepatitis B s antigen (HBsAg), hepatitis B e antigen 
(HBeAg), antibody to hepatitis B surface antigen (anti-HBs), 
antibody to hepatitis B e antigen (anti-HBe) and antibody to 
hepatitis B total c antigen (anti-HBc), which are valuable for the 
diagnosis and monitoring of hepatitis B infection and vaccina-
tion efficacy. Detection of serological markers has evolved from 
a cumbersome and time-consuming procedure by manual ra-
dioimmunoassay or enzyme-linked immunosorbent assay (ELI-
SA) to procedures with systems that partially or fully automate 
the process. Electrochemiluminescence immunoassay (ECLIA) 
is a new quantitatively analysis technique with improved both 
sensitivity and measurement ranges, shortened reaction period 
(approximately 18 minutes) and random-access capabilities for 
specimen, has been gradually applied to detect these antibodies 
and antigens.
2-4
The prevalence of HBV infection and HBsAg carrier rates 
vary with the particular population samples, ethnic groups 
studied and the detection methods used. China has had one of 
the highest rates of HBV endemicity in the world. Since a HBV 
vaccination program was implemented in 1992, the incidence of 
acute HBV infection in children has decreased dramatically. The 
HBsAg carrier rate decreased from 9.67% in 1992 to the current 
0.96% in children 1 to 4 years old and to 2.42% in children 5 to 
14 years old according to a serosurvey based on ELISA in 2006.
5 
The hospital children and adolescents are special populations, 
the present seroprevalence of HBV infection (especially since 
2006) among these based on ECLIA in China are still not well 
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understood. In this study, we aimed to investigate and under-
stand the present prevalence of hepatitis B infection and vac-
cination efficacy in Zhejiang children and adolescents based on 
the children’s hospital data during 2006 to 2010, and indirectly 
evaluate the effect of mass HBV vaccination program locally 
since 18 years after was launched.
MATERIALS AND METHODS
1. Screening criterion and subjects
This study is a retrospective analysis based on common labo-
ratory information system (LIS) data and no extra sera or tests 
were further required for the subjects. The investigation was ap-
proved by the Ethical Committee of Zhejiang University.
The Children’s Hospital of Zhejiang University is the only 
comprehensive and teaching hospital in Zhejiang Province. It 
has 850 beds which mainly serves local pediatric patients from 
Zhejiang Province. No hepatitis clinic and wards are available in 
this hospital, so no congregation of HBV infection individuals 
who will artificially cause elevated HBV seroprevalence. HBV 
serological screening panel including five markers was routinely 
employed for most outpatients and inpatients in this hospital, 
not only specifically for patients who have suspected liver prob-
lems. 
A total of 33,187 subjects were selected from LIS database 
during July 2006 to March 2010 according to the exclusion 
criterion consisting of non-first-time hepatitis results, >16 years 
older and whose living addresses are not in Zhejiang. Of 33,187 
patients, 21,187 boys and 12,000 girls, age ranged from 0 to 16 
years old. Of 33,187 subjects, 962 were outpatients, 32,225 were 
inpatients of whom 1,424 were from the Department of Inten-
sive Care Unit, 574 Neonatology, 1,333 Hematology/Oncology, 
7,642 General Surgery/Eye, Nose and Throat (ENT) Surgery, 
2,918 Cardiothoracic Surgery, 2,947 Urology Surgery/Oncol-
ogy Surgery, 3,581 Orthopedics/Neurosurgery/Burn and Plastic 
Surgery, 1,801 Gastroenterology, 543 Neurology, 1,465 Cardiol-
ogy, 2,997 Nephrology/Ophthalmology, 2,628 Endocrinology, 
and 2,372 Respiratory Medicine. Location distribution among 
all children and adolescents according to their living addresses 
were as follows: Hangzhou City (46.00%), Jinhua City (12.69%), 
Shaoxing City (10.03%), Jiaxing City (7.82%), Taizhou City 
(5.79%), Ningbao City (4.85%),  Huzhou City (4.17%), Wenzhou 
City (3.21%), Quzhou city (2.94%), Lishui City (1.94%), and 
Zhoushan City (0.56%). The constituent ratios of gender and age 
in entire subjects were shown in Table 1.
2. Detection of HBV serological markers
A routine test panel consisting of five serological markers 
was employed to monitor HBV infection or vaccination efficacy 
for patients in our hospital. If HBsAg, HBeAg, or anti-HBc was 




Boys (constitution) Girls (constitution) Boys (vaccination) Girls (vaccination)
No. % No. % Unk* Vac Unv %
† Unk* Vac Unv %
†
  0-1M 1,567 997  63.62  570  36.38  204  787  6  99.40  112 455  3 99.34 
  1M-1Y 8,352 5,215  62.44  3,137  37.56  37  5,148  30  99.42  18 3,106  13 99.58 
  1-2Y 4,665 3,090  66.24  1,575  33.76  12  3,052  26  99.16  5 1,556  14 99.11 
  2-3Y 2,675 1,677  62.69  998  37.31  12  1,650  15  99.10  8 981  9 99.09 
  3-4Y 2,141 1,335  62.35  806  37.65  11  1,311  13  99.02  2 797  7 99.13 
  4-5Y 1,938 1,201  61.97  737  38.03  15  1,174  12  98.99  8 723  6 99.18 
  5-6Y 1,816 1,164  64.10  652  35.90  11  1,140  13  98.87  7 634  11 98.29 
  6-7Y 1,737 1,128  64.94  609  35.06  13  1,103  12  98.92  6 593  10 98.34 
  7-8Y 1,469 918  62.49  551  37.51  14  893  11  98.78  4 540  7 98.72 
  8-9Y 1,423 866  60.86  557  39.14  21  825  20  97.63  6 539  12 97.82 
  9-10Y 1,208 728  60.26  480  39.74  17  692  19  97.33  11 455  14 97.01 
10-11Y 1,255 814 64.86  441 35.14  17  769  28 96.49  10 418  13 96.98 
11-12Y 1,141 768 67.31  373 32.69  11  733  24 96.83  7 354  12 96.72 
12-13Y 841 603 71.70  238 28.30  14  571  18 96.94  8 222  8 96.52 
13-14Y 522 396 75.86  126 24.14  6  367  23 94.10  4 116  6 95.08 
14-15Y 261 177 67.82  84 32.18  4  160  13 92.49  1 77  6 92.77 
15-16Y 176 110 62.50  66 37.50  2  101  7 93.52  1 61  4 93.85 
Total 33,187 21,187 63.85  12,000 36.16  421  20,476 290 98.62  218 11,627 155 98.68 
M, month; Y, year; Unk, unknown; Vac, vaccinated; Unv, unvaccinated.
*Subjects (421 boys and 218 girls) with unknown hepatitis B virus (HBV) vaccination; 
†The vaccinated numbers divided by sum of the vaccinated 
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positive for any subjects, anti-HBc (IgM) would be tested fur-
ther. Around 2 to 3 mL of venous blood for each subject was 
taken into vacuum-tube (BD, Franklin Lakes, NJ, USA) with 
coagulant, rested for at least half an hour at room temperature, 
then centrifuged for 3 minutes at 3,000 r/min to collect the 
sera. Five serological markers were detected on e601 analyzer 
(Roche  Diagnostics, Mannheim, Germany) according to Roche’s 
protocols by electrochemiluminescence immunoassay (ECLIA), 
where ‘sandwich principle’ for HBsAg, HBeAg, and anti-HBs, 
and ‘competition principle’ for anti-HBe and anti-HBc. The re-
sults for all samples reactive for HBsAg were confirmed by the 
confirmatory assays of Roche e601. All reagent kits, including 
calibrators and controls, were purchased from Roche Company 
and strictly used before the expiration date. Reference intervals 
for five serological markers were as follows: HBsAg <1 COI 
(cutoff index), HBeAg <1 COI, HBsAb <10 mIU/mL, HBeAb >1 
COI, and HBcAb >1 COI. 
3. Statistical analysis
Original data was sorted out by EXCEL 2003 (Microsoft Co., 
Redmond, WA, USA) and Statistical analyses were done by 
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) software. Com-
parison of likelihood ratio was analyzed by using chi-square test 
and probability level less than 0.05 was considered statistically 
significant. For convenient and practical purpose of statistical 
analysis, anti-HBs concentration >1,000 mIU/mL was denoted 
1,001 mIU/mL, <2 mIU/mL was denoted 1 mIU/mL. Additional-
ly, age ≤29 days referred to <1M, 30 days to 12 months referred 
to 1M-1Y, by analogy in this work (D, day; M, month, Y: year).
RESULTS
1. HBV vaccination coverage rates 
Brief HBV vaccination history is one of the routine contents 
in a case record for every patient in this hospital, but detailed 
three-dose HBV vaccination is not recorded. A total of 31,548 
children were selected for the analysis of HBV vaccination 
coverage rates except 639 children (mostly neonates) with un-
known HBV vaccination. Average HBV vaccination coverage 
rates among 20,766 boys and 11,782 girls were 98.62% and 
98.68%, respectively (Table 1). 
2. Seventeen serological patterns of hepatitis B
Seventeen serological patterns of hepatitis B were found out 
of 33,187 pediatric patients. Entire patterns and their distribu-
tion among these subjects were shown in Table 2. Four high-







No. % No. % No. %
1 - + - - - 20,587 62.033 13,150 62.066 7,437 61.975 0.027 0.869
2 - - - - - 7,785 23.458 5,008 23.637 2,777 23.142 1.047 0.312
3 - + - - + 2,702 8.142 1,696 8.005 1,006 8.383 1.467 0.226
4 - + - + + 1,222 3.682 750 3.540 472 3.933 3.343 0.068
5 - - - - + 283 0.853 196 0.925 87 0.725 3.628 0.057
6 - + - + - 198 0.597 103 0.486 95 0.792 12.058 0.001
7 + - + - + 158 0.476 117 0.552 41 0.342 7.168 0.007
8 - - - + + 104 0.313 69 0.326 35 0.292 0.284 0.594
9 - - - + - 56 0.169 34 0.160 22 0.183 0.238 0.626
10 + - - + + 38 0.115 31 0.146 7 0.058 5.185 0.023
11 + - + - - 25 0.075 18 0.085 7 0.058 0.721 0.533
12 - + + - - 13 0.039 8 0.038 5 0.042 0.000
† 1.000
13 + + + - - 5 0.015 3 0.014 2 0.017 0.000
† 1.000
14 + - - - - 4 0.012 2 0.009 2 0.017 0.003
† 0.955
15 + - - - + 4 0.012 1 0.005 3 0.025 1.202
† 0.273
16 + + - - - 2 0.006 1 0.005 1 0.008 0.000
† 1.000
17 - - + - + 1 0.003 0 0.000 1 0.003 0.083
† 0.773
Total 33,187 100 21,187 100 12,000 100
All percentages in this table were reserved three decimal places but rounded to two decimal places when cited in the paper. 
ECLIA, electrochemiluminescence immunoassay.
*Display sequence of five markers in a hepatitis B virus (HBV) screening panel: hepatitis B s antigen (HBsAg), antibody to hepatitis B surface anti-
gen (anti-HBs), hepatitis B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe), and antibody to hepatitis B total c antigen (anti-HBc), 
respectively. +: positive, -: negative; 
†Corrected χ
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frequency patterns from pattern one to four were ‘anti-HBs 
(+) alone’ (62.03%), ‘negative pattern’ (23.46%), ‘anti-HBc (+) 
anti-HBs (+)’ (8.14%) and ‘anti-HBe (+) anti-HBc (+) anti-HBs 
(+)’ (3.68%). The positive rates of other thirteen low-frequency 
patterns from pattern five to seventeen varied from 0.003% to 
0.86% and no HBcAb-IgM was found in any of subjects. Except 
for ‘negative pattern’, ‘HBsAg (+) HBeAg (+) anti-HBc (+)’, ‘HB-
sAg (+) anti-HBe (+) anti-HBc (+)’ and ‘anti-HBe (+) anti-HBs 
(+)’, no significant differences were found between the distribu-
tion ratios and corresponding gender groups by chi-square test 
(p>0.05). 
3. Anti-HBs (+), ‘negative’ and HBsAg (+) 
The detailed distribution and trend in three patterns of anti-
HBs (+), negative and HBsAg (+) were shown in Table 3 and Fig. 
1. A total of 260 subjects had HBsAg positive from 7 patterns 
(pattern 7, 10, 11, 13, 14, 15, 16) and the overall rate of sero-
positivity was relatively low (0.71%). The positive rate of HBsAg 
slowly went up with age, from 0.13% to 0.88% in the aged of ≤ 
8 years and from 1.16% to 3.83% in the age of > 8 years, lowest 
in the age of <1M and highest in the age of 13 to14 years.
Of 24,730 anti-HBs positive subjects, 20,587 were ‘anti-HBs 
(+) alone’ (85.259%), and the highest positive rate was 92.35% 
in the age of 1 to 2 years, followed by 81.05% in the age of 2 to 
3 years, while the lowest positive rate was 44.06% in the age of 
14 to 15 years. 
Of 7,785 ‘negative pattern’ subjects, the lowest negative rate 
was 7.37% in the age of 1 day to 2 years, while highest nega-
tive rate was 51.34% in the age of 14 to 15 years. A trend of 
correspondingly reverse change between rates of ‘anti-HBs (+)’ 
and ‘negative pattern’ with age was found. Positive rate of anti-
HBs increased with age after birth, peaked at 2 years of age, 
declined slowly up to 5 years of age and remained stationary up 
Fig. 1. Trends of the three hepatitis B virus patterns with respect to 
age. 
M, month; Y, year; HBsAg, hepatitis B surface antigen; anti-HBs, an-
tibody to hepatitis B surface antigen.
Table 3. Distribution Characteristics of ‘Anti-HBs (+)’, ‘Negative’ and ‘HBsAg (+)’ Patterns among Children and Adolescents in Different Age 
Groups
Age Total no.
Total anti-HBs (+) Total HBsAg (+) Negative
No. % No. % No. %
        0-1M 1,567 977 62.35 2 0.13 443 28.27
  1M-1Y 8,352 7,372 88.26 19 0.23 778 9.31
  1-2Y 4,665 4,308 92.35 16 0.34 344 7.37
  2-3Y 2,675 2,168 81.05 10 0.37 488 18.24
  3-4Y 2,141 1,509 70.48 12 0.56 612 28.58
  4-5Y 1,938 1,271 65.58 17 0.88 642 33.13
  5-6Y 1,816 1,202 66.19 8 0.44 602 33.15
  6-7Y 1,737 1083 62.35 10 0.58 629 36.21
  7-8Y 1,469 919 62.56 9 0.61 523 35.60
  8-9Y 1,423 846 59.45 18 1.26 552 38.79
  9-10Y 1,208 713 59.02 14 1.16 477 39.49
10-11Y 1,255 747 59.52 23 1.83 472 37.61
11-12Y     1,141 658 57.67 20 1.75 453 39.70
12-13Y 841 478 56.84 23 2.73 336 39.95
13-14Y 522 268 51.34 20 3.83 229 43.87
14-15Y 261 115 44.06 9 3.45 134 51.34
15-16Y 176 96 54.55 6 3.41 71 40.34
Total 33,187 24,730 74.52 236 0.71 7,785 23.46
M, month; Y, years; anti-HBs, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen. 214  Gut and Liver, Vol. 5, No. 2, June 2011
to 15-18 years of age. While rate of ‘negative pattern’ decreased 
after birth, dropped to the nadir at 2 years of age, then went up 
slowly up to 5 years of age and remained stationary up to 15-
18 years of age. 
4. Distribution of anti-HBs concentrations among age 
groups
Detailed distribution characters of 24,730 children among 
three anti-HBs levels and age were shown in Table 4. 
DISCUSSION
Hospital children and adolescents are special populations, 
whereas, the present seroprevalence of HBV infection and vac-
cination efficacy (especially since the nationwide serosurvey 
in 2006) among these populations based on ECLIA in China 
are still not well understood. In this study, seventeen serologi-
cal patterns of hepatitis B were found among 33,187 pediatric 
patients, where the dominant pattern was ‘anti-HBs (+) alone’ 
(62.03%), followed by ‘negative pattern’ (23.46%), ‘anti-HBc (+) 
anti-HBs (+)’ (8.14%) and ‘anti-HBe (+) anti-HBc (+) anti-HBs (+)’ 
(3.68%). The positive rates of other thirteen low-frequency pat-
terns varied from 0.003% to 0.86%. No significant differences 
were found between the distribution ratios and corresponding 
gender groups in most patterns by chi-square test.  
Classification of an HBV infection requires the identification 
of several serologic markers or patterns which imply the dif-
ferent clinical significance. Interpretation of various serological 
profiles of hepatitis B has been described in some studies.
6-8   
Pattern 1 is usually suggestive of successful hepatitis B vacci-
nation where anti-HBs alone is present and pattern 3 indicates 
natural immunization due to the presence of anti-HBs antibod-
ies along with anti-HBc (IgG). Pattern 2 shows individuals are 
free of HBV infection but are susceptible to HBV. Pattern 7, 
10, 11, 13, 14, 15, and 16 mean active infection of HBV while 
pattern 3, 4, 6, 8, and 9 mean past infection of HBV. Pattern 5 
is ‘anti-HBc alone’ which means probably active infection. Al-
hababi et al.
9 found ‘anti-HBc alone’ is a common phenomenon 
in the clinical virology laboratory but only a small proportion of 
samples had detectable HBV DNA. Knöll et al.
10 also pointed out 
that no evidence was found that HBV alone causes severe liver 
damage in individuals with ‘anti-HBc alone.’ Interestingly, there 
were three rare patterns, pattern 12 ‘HBeAg (+) anti-HBs (+)’, 
pattern 13 ‘HBsAg (+) HBeAg (+) anti-HBs (+)’ and pattern 16 
‘HBsAg (+) anti-HBs (+)’, because technically HBsAg or HBeAg, 
and anti-HBs will not simultaneously present in same individu-
als. Wang et al.
11 unveiled that HBeAg can cross the human 
placenta and disappears from serum within 6 months in most 
babies. Qiu et al. found in the Hangzhou cohort of 638 mothers, 
hepatitis B positive rate was 6.0%.
12 Our investigation showed 
Table 4. Distribution Characteristics of 24,730 Children and Adolescents with Total Anti-HBs Positive Markers in the Three Anti-HBs Concentra-
tion Ranges
Age Total no.
10-100 mIU/mL 100-1,000 mIU/mL  >1,000 mIU/mL
No. % No. % No. %
  0-1M 977 265 27.12 531 54.35 181 18.53
  1M-1Y 7,372 1,524 20.67 3,568 48.40 2,280 30.93
  1-2Y 4,308 1,127 26.16 2385 55.36 796 18.48
  2-3Y 2,168 1,081 49.86 919 42.39 168 7.75
  3-4Y 1,509 874 57.92 502 33.27 133 8.81
  4-5Y 1,271 718 56.49 377 29.66 176 13.85
  5-6Y 1,202 623 51.83 367 30.53 212 17.64
  6-7Y 1,083 480 44.32 327 30.19 276 25.48
  7-8Y 919 391 42.55 315 34.28 213 23.18
  8-9Y 846 329 38.89 330 39.01 187 22.10
  9-10Y 713 305 42.78 268 37.59 140 19.64
10-11Y 747 354 47.39 285 38.15 108 14.46
11-12Y     658 322 48.94 255 38.75 81 12.31
12-13Y 478 250 52.30 157 32.85 71 14.85
13-14Y 268 163 60.82 85 31.72 20 7.46
14-15Y 115 61 53.04 42 36.52 12 10.43
15-16Y 96 55 57.29 29 30.21 12 12.50
Total 24,730 8,922 36.08 10,742 43.44 5,066 20.49
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that 13 children with pattern 12 were below 3 months of age 
and all were born to HBeAg (+) mothers. We speculated these 
HBeAg in these children came transplacentally from their moth-
ers’ sera and anti-HBs antibodies probably were the efficacy of 
vaccination. Therefore, the present of HBeAg in certain children 
aged below 6 months may not mean real HBV infection, mak-
ing it is necessary to further monitor them. The coexistence of 
HBsAg and anti-HBs even HBeAg in pattern 13 and 16 were 
found, in principle, HBsAg and anti-HBs simultaneously present 
in same individuals is also rarely seen. In 3 cases, all anti-HBs 
were in 10 to 100 mIU/mL range while HBsAg was elevated. 
The real reason for this phenomenon was unclear but may be 
associated with infection of different HBV subtypes, transient 
HBsAg positive (mostly found at 6 days after hepatitis B immu-
nization) or false positivity due to measurement methods.
2,13-15
The dominant patterns of HBV were further discussed below. 
HBsAg is the first marker to appear in patient serum, and the 
presence of this antigen indicates an ongoing infection with 
HBV and is detectable in both acutely ill patients and chronic 
carriers of HBV, thus the importance of accurate testing for this 
marker. In this study, a total of 236 children had HBsAg posi-
tive and the overall seroprevalence of HBsAg was 0.71%. The 
trend of overall HBsAg carrier rate were found, slowly went 
up with ages, lowest in the age of <1M and highest in the age 
of 13 to14 years. Our overall HBsAg carrier rate was slightly 
lower than those in children 1 to 4 years old (0.96%) and 5 to 
14 years old (2.42%) from a nationwide serosurvey conducted 
in 2006,
5 and significantly lower than those in Chinese adults 
(around 7.0%) as well.
5,16 Compared with international studies, 
our overall HBsAg carrier rate was lower than those in 1,500 
Libyan neonates (0.9%),
17 229 healthy Indonesian children born 
during 1994-1999 (3.1%),
18 and 251 Nigerian children (12.4%).
19 
Obviously, HBsAg seroprevalence rate in Zhejiang children has 
decreased dramatically. The maternal HBsAg situations of 236 
HBsAg positive children were investigated, 35 unknown, 149 
HBsAg positive and 52 HBsAg negative, which indicated verti-
cal transmission of HBV from mother to child is a main infec-
tion route in children.
Either an HBV infection or HBV vaccination can cause the 
anti-HBs marker to be positive. It is an immune globulin se-
creted by B lymph cells that can combine with the HBsAg to 
neutralize it. Along with other immune reactions, the anti-
HBs protective antibody can eradicate the invading HBV from 
the body. This antibody can exist in the blood for a long time, 
gradually decreasing with age. In this study, a total of 24,730 
children were anti-HBs positive (74.54%) and 20,587 were ‘anti-
HBs (+) alone’ (62.03%). Our anti-HBs positive rate was similar 
to those in Taiwan where the anti-HBs-seropositive rates were 
83.1%, 53.0%, and 53.5% for participants who were born before 
1984 when universal hepatitis B vaccination program for new-
borns was launched, 1984-1986 and after 1986. The higher the 
level of anti-HBs, the longer the duration of persistence of anti-
body. The persistence of anti-HBs depends on the peak antibody 
level achieved after three doses.
14 In present study, three kinds 
of anti-HBs levels (10-100 mIU/mL, 100-1,000 mIU/mL, and 
>1,000 mIU/mL) in anti-HBS positive children were 36.08%, 
43.43%, and 20.49%, respectively.
‘Negative pattern’ denotes individuals are free of HBV infec-
tion but is susceptible populations to HBV. A total of 7,785 chil-
dren harbored ‘negative pattern’ (23.46%), the lowest negative 
rate was 7.37% in the age of 1 to 2 years while highest negative 
rate was 51.34% in the age of 14 to 15 years. The present of 
‘negative pattern’ in local children were associated with unre-
sponsiveness to HBsAg, absence or insufficiency of vaccination, 
natural disappearance of anti-HBs. Liang et al.
20 reported the 
efficacy of hepatitis B vaccination with a timely birth dose was 
88.3% in Chinese children, while a study in Israel showed that 
22.9% of local children were nonresponser.
21 Unresponsiveness 
to HBsAg has been attributed to a number of environmental 
and genetic factors, the most important ones being the haplo-
type of HLA antigens and immunological tolerance.
21,22 Liang et 
al.
20 also found HBV vaccine coverage (3 doses) has increased to 
93.4% for Chinese children born in 2005. Zhang et al.
23 revealed 
The weighted complete HBV vaccine coverage was 99.66%, 
89.95%, and 13.21% in the age group of 1 to 4 years old, 5 to 
14 years old, and 15 to 59 years old in Shandong Province, 
respectively. In this study, average HBV vaccination coverage 
rates among 20,766 boys and 11,782 girls were 98.62% (92.49-
99.42%) and 98.68% (92.77-99.58%), respectively. We believed 
the lacking or insufficiency of HBV vaccination in Zhejiang 
children exists. We suggested a HBV vaccination catch-up cam-
paign should be conducted in the older children in Zhejiang and 
further efforts should be made to improve HBV vaccine cover-
age among the high risk population for enhancement of hepati-
tis B control. 
It is well known that HBV vaccination is most efficient 
measure to prevent and decrease HBV infection around the 
world.
16,22,24-26 China has been one of the highest rates of HBV 
endemicity in the world, However, Since HBV vaccination 
program was implemented in 1992, the HBsAg carrier rate in 
general population dropped from 9.75% in 1992 to 7.18% in 
2006 and reduced to 1.0% among children born after 1999.
16,20 
Reduced HBsAg prevalence was strongly associated with vac-
cination among all age groups.
16 China has now fallen from 
high endemic area with HBsAg seroprevalence ≥8% into the 
intermediate endemic area where HBsAg prevalence in general 
population is 2-7%, according to the WHO’s category of HBV 
endemicity. Zhejiang Province is relatively developed area in 
the eastern China where the healthcare system is much better 
and more efficient than other provinces. Our study demon-
strated that the rates of relatively high anti-HBs-positive and 
low HBsAg seroprevalence were present in hospital children 
and adolescents, which was also indirectly showed that the HBV 
vaccination program was successful and valuable to prevent 216  Gut and Liver, Vol. 5, No. 2, June 2011
and decrease HBV infection in Zhejiang. 
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